TY - JOUR
T1 - European Respiratory Society statement on frailty in adults with chronic lung disease
AU - Osadnik, Christian R.
AU - Brighton, Lisa J.
AU - Burtin, Chris
AU - Cesari, Matteo
AU - Lahousse, Lies
AU - Man, Will D.C.
AU - Marengoni, Alessandra
AU - Sajnic, Andreja
AU - Singer, Jonathan P.
AU - ter Beek, Lies
AU - Tsiligianni, Ioanna
AU - Varga, Janos T.
AU - Pavanello, Stefano
AU - Maddocks, Matthew
N1 - Funding Information:
Conflict of interest: The task force members report no conflicts of interest for the present work, but acknowledge the following roles and funding sources during the conduct of this work. C.R. Osadnik received a Rebecca L. Cooper Medical Research Foundation project grant (2020–21) and an education grant from GSK Australia, paid to his institution, and delivered an educational lecture for Novartis Australia, all outside of the present work. L.J. Brighton is supported by the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust, and is funded by an Economic and Social Research Council Post-Doctoral Fellowship (ES/X005259/1). L. Lahousse reports external expert consultation for AstraZeneca and lectures for Chiesi and IPSA vzw, a non-profit organisation facilitating lifelong learning for healthcare providers, (to be) paid to her institution, outside this manuscript. W.D.C. Man is supported by National Institute for Health and Care Research (NIHR) Research for Patient Benefit awards (PB-PG-0816-20022 and PB-PG-0317-20032) and a NIHR Artificial Intelligence Award (AI_AWARD02204). A. Marengoni received fees for lectures provided to Vyvamed and Oliba. A. Sajnic reports advisory board membership for AstraZeneca and delivery of a lecture for Roche. J.P. Singer reports funding (NHLBI U01HL163242, U01HL145435, R01HL134851) and scientific advisory board membership for Altavant Sciences and Mallinckrodt Pharmaceuticals. I. Tsiligianni reports grants/advisory boards all unrelated to the current work from Novartis, GSK, Boehringer Ingelheim, AstraZeneca and Chiesi. J.T. Varga reports unrelated grants/advisory boards from Chiesi and Boehringer Ingelheim. S. Pavanello is president of Unione Trapiantati Polmone, Padua, Italy. M. Maddocks is supported by a National Institute for Health and Care Research (NIHR) Career Development Fellowship (CDF-2017–10-009) and the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust. The remaining authors have no potential conflicts of interest to disclose.
Publisher Copyright:
© The authors 2023.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Frailty is a complex, multidimensional syndrome characterised by a loss of physiological reserves that increases a person's susceptibility to adverse health outcomes. Most knowledge regarding frailty originates from geriatric medicine; however, awareness of its importance as a treatable trait for people with chronic respiratory disease (including asthma, COPD and interstitial lung disease) is emerging. A clearer understanding of frailty and its impact in chronic respiratory disease is a prerequisite to optimise clinical management in the future. This unmet need underpins the rationale for undertaking the present work. This European Respiratory Society statement synthesises current evidence and clinical insights from international experts and people affected by chronic respiratory conditions regarding frailty in adults with chronic respiratory disease. The scope includes coverage of frailty within international respiratory guidelines, prevalence and risk factors, review of clinical management options (including comprehensive geriatric care, rehabilitation, nutrition, pharmacological and psychological therapies) and identification of evidence gaps to inform future priority areas of research. Frailty is underrepresented in international respiratory guidelines, despite being common and related to increased hospitalisation and mortality. Validated screening instruments can detect frailty to prompt comprehensive assessment and personalised clinical management. Clinical trials targeting people with chronic respiratory disease and frailty are needed.
AB - Frailty is a complex, multidimensional syndrome characterised by a loss of physiological reserves that increases a person's susceptibility to adverse health outcomes. Most knowledge regarding frailty originates from geriatric medicine; however, awareness of its importance as a treatable trait for people with chronic respiratory disease (including asthma, COPD and interstitial lung disease) is emerging. A clearer understanding of frailty and its impact in chronic respiratory disease is a prerequisite to optimise clinical management in the future. This unmet need underpins the rationale for undertaking the present work. This European Respiratory Society statement synthesises current evidence and clinical insights from international experts and people affected by chronic respiratory conditions regarding frailty in adults with chronic respiratory disease. The scope includes coverage of frailty within international respiratory guidelines, prevalence and risk factors, review of clinical management options (including comprehensive geriatric care, rehabilitation, nutrition, pharmacological and psychological therapies) and identification of evidence gaps to inform future priority areas of research. Frailty is underrepresented in international respiratory guidelines, despite being common and related to increased hospitalisation and mortality. Validated screening instruments can detect frailty to prompt comprehensive assessment and personalised clinical management. Clinical trials targeting people with chronic respiratory disease and frailty are needed.
UR - http://www.scopus.com/inward/record.url?scp=85168240741&partnerID=8YFLogxK
U2 - 10.1183/13993003.00442-2023
DO - 10.1183/13993003.00442-2023
M3 - Article
C2 - 37414420
AN - SCOPUS:85168240741
SN - 0903-1936
VL - 62
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 2
M1 - 2300442
ER -
